Fig. 15From: Ligand-based drug design of quinazolin-4(3H)-ones as breast cancer inhibitors using QSAR modeling, molecular docking, and pharmacological profiling2D and 3D Interactions of designed compound 1 with the active site of the EGFR receptorBack to article page